Atrial fibrillation, bleeding, and coronary intervention: current recommendations

Area of Science:

• Cardiology
• Pharmacology
• Thrombosis Research

Background:

• Increasing prevalence of patients requiring both oral anticoagulation for atrial fibrillation (AF) and dual antiplatelet therapy (DAPT) post-percutaneous coronary intervention (PCI).
• Triple therapy (oral anticoagulation, aspirin, P2Y12 inhibitor) is associated with a high bleeding risk.
• Uncertainty exists regarding optimal drug combinations and treatment durations for these patients.

Purpose of the Study:

• To review the pathophysiology of thrombus formation in AF and coronary artery disease.
• To summarize current post-PCI treatment strategies and guidelines for AF patients.
• To discuss stent selection, bleeding risk assessment, and mitigation strategies.

Main Methods:

• Literature review of recent studies on non-vitamin K antagonist oral anticoagulant (NOAC) safety in combination therapies.
• Analysis of clinical trial data and guideline recommendations for dual and triple therapies.
• Discussion of pathophysiological mechanisms and risk stratification tools.

Main Results:

• Growing evidence supports the feasibility and safety of dual therapy (oral anticoagulation plus a P2Y12 inhibitor) in select patients.
• NOACs show promise in reducing bleeding risk compared to traditional anticoagulants in combination regimens.
• Individualized treatment strategies are crucial for optimizing efficacy and safety.

Conclusions:

• Dual therapy represents a viable alternative to triple therapy for many AF patients post-PCI, reducing bleeding risk.
• Careful patient selection, appropriate stent choice, and bleeding risk assessment are essential.
• Further research is needed to refine optimal treatment durations and combinations for specific patient profiles.